Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Pfizer’s LORBRENA® CROWN Trial Reveals Most ALK-Positive Advanced Lung Cancer Patients Surviving Over Five Years Without Disease Progression

NextEdge Admin

01 Jun 2024

3 min 9 sec

Pfizer Inc. (NYSE: PFE) revealed extended outcomes from the Phase 3 CROWN trial comparing LORBRENA® (lorlatinib) to XALKORI® (crizotinib) in previously untreated ALK-positive advanced non-small cell lung cancer (NSCLC). With five years of median follow-up, LORBRENA demonstrated unprecedented efficacy, showcasing a median progression-free survival (PFS) not reached and an 81% reduction in disease progression or death compared to XALKORI. Remarkably, 60% of patients on LORBRENA remained without disease progression after five years, contrasting with 8% on XALKORI. These findings were presented at the 2024 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

Dr. Roger Dansey, Pfizer’s Chief Development Officer, hailed these results as groundbreaking, underscoring Pfizer’s dedication to pioneering breakthroughs. Lung cancer, the leading cause of cancer-related deaths globally, affects about 234,580 new cases in the U.S. annually, with NSCLC comprising 80-85% of cases and ALK-positive tumors occurring in 3-5% of NSCLC instances. LORBRENA, designed by Pfizer to combat ALK mutations and penetrate the blood-brain barrier, showcased significant benefits in ALK-positive NSCLC patients.

Principal Investigator of the CROWN trial, Dr. Benjamin Solomon, noted that LORBRENA prolonged survival without disease progression, with most patients experiencing sustained benefits for over five years, including robust protection against brain metastases. The updated analysis revealed a staggering 94% reduction in the risk of intracranial progression with LORBRENA compared to XALKORI.

Kenneth Culver, MD, Director of Research at ALK Positive, emphasized the pivotal role of these results in advancing ALK-positive lung cancer treatment. Despite ALK-positive NSCLC representing a small portion of cases, the improvements signify substantial progress in targeted therapy.

Safety profiles of LORBRENA and XALKORI remained consistent, with no new safety concerns for LORBRENA. Common adverse events mirrored earlier findings, with grade 3/4 adverse events occurring more frequently in the LORBRENA group.

Pfizer continues its commitment to accessibility by providing plain language summaries of its research for non-scientists interested in understanding the latest findings presented at ASCO.